Back to Authors

Mielke, Michelle M.

https://orcid.org/0000-0001-7177-1185

A5090710393 | I4405269449

Mayo Clinic

Wake Forest University Health Sciences

Citations 530

P1‐131: Excessive daytime sleepiness is comparable in behavioral variant frontotemporal dementia and Alzheimer's disease dementia but greater in dementia with lewy bodies

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2015.06.329

O3‐01‐02: Treatment with 17β‐estradiol in postmenopausal women is associated with lower PiB‐PET retention

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2015.07.237

IC‐P‐151: Longitudinal outcomes and profiles of distinct biomarker clusters based on vascular disease, neurodegeneration, and amyloid deposition

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2015.06.174

F5‐04‐04: Scd in a population‐based sample: Progression to MCI

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_6 | Pages: No page available

10.1016/j.jalz.2015.07.438

O2‐09‐03: Evidence of reduced neuronal plasticity to education in ApoE‐ɛ4 carriers

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2015.07.179

P2‐170: Plasma ceramides predict age‐related differences in white matter microstructure

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2015.06.709

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

JAMA Neurology | November 23, 2015 | Volume: 73 | Issue: 1 | Pages: 85

10.1001/jamaneurol.2015.3098 | PMID 26595683

Influence of amyloid and APOE on cognitive performance in a late middle‐aged cohort

Alzheimer's & Dementia | November 19, 2015 | Volume: 12 | Issue: 3 | Pages: 281-291

10.1016/j.jalz.2015.09.010 | PMID 26602629

AbstractIntroductionFew studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle‐aged individuals.MethodsWe included 464 cognitively normal, test‐naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51–71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow‐up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline.ResultsElevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE ɛ4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test.DiscussionElevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.
Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia

JAMA Neurology | November 16, 2015 | Volume: 73 | Issue: 1 | Pages: 93

10.1001/jamaneurol.2015.2952 | PMID 26569387

Atrial fibrillation, cognitive impairment, and neuroimaging

Alzheimer's & Dementia | October 25, 2015 | Volume: 12 | Issue: 4 | Pages: 391-398

10.1016/j.jalz.2015.08.164 | PMID 26607820

AbstractIntroductionThe objective of our study was to investigate cross‐sectional associations of atrial fibrillation with neuroimaging measures of cerebrovascular disease and Alzheimer's disease and their interactions with mild cognitive impairment (MCI).MethodsMagnetic resonance imaging scans of individuals from a population‐based study were analyzed for infarctions, total gray matter, and hippocampal and white matter hyperintensity volumes. A subsample underwent positron emission tomography imaging.ResultsAtrial fibrillation was associated with infarctions and lower total gray matter volume. Compared with subjects with no atrial fibrillation and no infarction, the odds ratio (95% confidence intervals) for MCI was 2.99 (1.57–5.70; P = .001) among participants with atrial fibrillation and infarction, 0.90 (0.45–1.80; P = .77) for atrial fibrillation and no infarction, and 1.50 (0.96–2.34; P = .08) for no atrial fibrillation and any infarction.DiscussionParticipants with both atrial fibrillation and infarction are more likely to have MCI than participants with either infarction or atrial fibrillation alone.